Acquired aplastic anemia (AA) is an immune-mediated bone marrow (BM) failure where
marrow disruption is driven by a cytotoxic T-cell–mediated autoimmune attack against …

Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …

Pancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and
the diagnosis is confirmed after careful evaluation, following exclusion of alternate diagnosis …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

Abstract Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of
allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia …

Idiopathic aplastic anemia (IAA) pathophysiology is dominated by autoreactivity of human
leukocyte antigen (HLA)-restricted T-cells against antigens presented by hematopoietic stem …

Therapy-related myeloid neoplasms (tMN) are complications of cytotoxic therapies. Risk of
tMN is high in recipients of autologous hematopoietic stem cell transplantation (aHSCT) …

Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by
morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic …

The recent application of whole exome or whole genome sequencing unveiled a plethora of
germline variants predisposing to myeloid disorders, particularly myelodysplastic …

For the last 20 years, therapy of paroxysmal nocturnal hemoglobinuria (PNH) relied—up
until recently—on antibody based terminal complement inhibitionon. PNH pathophysiology …